Chokri Ben Lamine: Routine VTE Prophylaxis Is Not Recommended for Chronically Bedridden Patients at Home
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Short answer (guideline-based): NO routine VTE prophylaxis for chronically bedridden patients at home.
Guideline Position
American College of Chest Physicians (CHEST Guidelines)
Do Not recommend pharmacologic prophylaxis for:
- Chronically immobilized patients
- Nursing home residents
- Home-bound patients without acute illness
Rationale:
- Lower VTE incidence vs hospitalized patients
- Higher bleeding risk outweighs benefit
American Society of Hematology (ASH 2018/2021 VTE Guidelines)
Suggest against routine prophylaxis in:
- Long-term immobile patients at home
- Unless additional strong transient risk factors present
When to Consider prophylaxis (exception cases)
Only if HIGH-RISK transient state, e.g.:
- Recent hospitalization (≤45–90 days)
- Active cancer (especially receiving chemotherapy)
- Prior VTE
- Acute infection or inflammation
- Marked reduced mobility with additional risk (Improce score high)
In such cases, short-term prophylaxis may be considered on a case-by-case basis.
Extended prophylaxis trials (important nuance)
- MAGELLAN trial
- APEX trial
- MARINER trial
Show benefit in selected high-risk recently hospitalized patients, Not applicable to stable chronically bedridden home patients
Practical Hematology Take
- Bedridden status alone is not an indication
- Always balance: VTE risk vs bleeding risk
- Focus on:
- Hydration
- Mobilization if possible
- Reassess if clinical status changes
Key References
- Kahn SR et al. CHEST Guideline (2012, updated concepts)
- Spyropoulos AC et al., MARINER Trial (NEJM 2018)
- Cohen AT et al., MAGELLAN Trial (NEJM 2013)
One-line clinical answer
No routine pharmacologic VTE prophylaxis for chronically bedridden patients at home unless additional high-risk transient factors are present.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies